Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

Molecular Cancer Therapeutics

Volumn 8, Issue 6, 2009, Pages 1460-1472

  Eguchi, Tomohiro ^a   Itadani, Hiraku ^a   Shimomura, Toshiyasu ^a   Kawanishi, Nobuhiko ^a   Hirai, Hiroshi ^a   Kotani, Hidehito ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAMPTOTHECIN; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2C; FLAVOPIRIDOL; MACROCYCLIC COMPOUND; MESSENGER RNA; PACLITAXEL; PROTEIN MCL 1; PROTEIN P16; PROTEIN P18; QUINOXALIN 2 ONE DERIVATIVE; QUINOXALINE DERIVATIVE; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; ROSCOVITINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOPRECIPITATION; MARKER GENE; MICROARRAY ANALYSIS; NONHUMAN; P18 INK4C GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; TUMOR CELL LINE; WESTERN BLOTTING; ANIMAL; ARMYWORM; CELL CYCLE; CELL LINE; CELL STRAIN HCT116; CHEMISTRY; DNA MICROARRAY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HELA CELLS; HUMANS; MACROCYCLIC COMPOUNDS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOXALINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SPODOPTERA; TRANSFECTION;

EID: 67649383621     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1159     Document Type: Article

References (50)

1. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-3695 (Pubitemid 32204552)
2. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103:127-140
3. Arata Y, Fujita M, Ohtani K, Kijima S, Kato JY. Cdk2-dependent and - independent pathways in E2F-mediated S phase induction. J Biol Chem 2000;275:6337-6345 (Pubitemid 30129927)
4. Li HY, Zheng Y. Phosphorylation of RCC1 in mitosis is essential for producing a high RanGTP concentration on chromosomes and for spindle assembly in mammalian cells. Genes Dev 2004;18:512-527 (Pubitemid 38372809)
5. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-1169
6. 1-phase progression. Genes Dev 1999;13:1501-1512
7. Meinhart A, Kamenski T, Hoeppner S, Baumli S, Cramer P. A structural perspective of CTD function. Genes Dev 2005;19:1401-1415 (Pubitemid 41003005)
8. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-646 (Pubitemid 16008560)
9. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55:1-14. (Pubitemid 46038884)
10. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996;69:247-253 (Pubitemid 26298285)
11. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-112 (Pubitemid 41039110)
12. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-225 (Pubitemid 27064709)
13. Bai F, Pei XH, Pandolfi PP, Xiong Y. p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. Mol Cell Biol 2006;26:4564-4576 (Pubitemid 43877575)
14. Damo LA, Snyder PW, Franklin DS. Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways. Mol Carcinog 2005;42:109-120
15. Cai D, Latham VM, Jr., Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006;66:9270-9280 (Pubitemid 44521149)
16. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999;96:4325-4329 (Pubitemid 29190335)
17. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399-5407 (Pubitemid 40827353)
18. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-468
19. Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006;12:7222-7231 (Pubitemid 46095393)
20. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726 (Pubitemid 34111379)
21. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-1300 (Pubitemid 44706932)
22. Ikuta M, Kamata K, Fukasawa K, et al. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J Biol Chem 2001;276:27548-27554 (Pubitemid 37410674)
23. Kawanishi N, Sugimoto T, Shibata J, et al. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin- 2-one structure. Bioorg Med Chem Lett 2006;16:5122-5126
24. 2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene 2007;26:509-520
25. Komatani H, Morita M, Sakaizumi N, et al. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. Cancer Res 1999;59:2701-2708 (Pubitemid 29269119)
26. 1/S cyclin-dependent kinases. J Biol Chem 1997;272:12738-12746
27. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-170 (Pubitemid 32328317)
28. Nakatsu N, Yoshida Y, Yamazaki K, et al. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther 2005;4:399-412. (Pubitemid 40443925)
29. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-2681
30. Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000;19:3496-3506 (Pubitemid 30428227)
31. Leone PE, Walker BA, Jenner MW, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008;14:6033-6041
32. Uziel T, Zindy F, Xie S, et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 2005;19:2656-2667 (Pubitemid 41627933)
33. Wiedemeyer R, Brennan C, Heffernan TP, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 2008;13:355-364
34. Solomon DA, Kim JS, Jenkins S, et al. Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 2008;68:2564-2569 (Pubitemid 351556252)
35. Kirsch M, Morz M, Pinzer T, Schackert HK, Schackert G. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosomes Cancer 2009;48:143-154
36. Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998;12:2899-2911 (Pubitemid 28440148)
37. Morishita A, Masaki T, Yoshiji H, et al. Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma. Hepatology 2004;40:677-686 (Pubitemid 39265590)
38. Forget A, Ayrault O, den Besten W, Kuo ML, Sherr CJ, Roussel MF. Differential post-transcriptional regulation of two Ink4 proteins, p18 Ink4c and p19 Ink4d. Cell Cycle 2008;7:3737-3746
39. Cai D, Byth KF, Shapiro GI. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 2006;66:435-444
40. Dib A, Peterson TR, Raducha-Grace L, et al. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div 2006;1:23. (Pubitemid 46731034)
41. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002;21:1359-1369 (Pubitemid 34214501)
42. Dai Y, Hamm TE, Dent P, Grant S. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107-, and E2F-dependent S phase entry. Cell Cycle 2006;5:437-446
43. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003;2:73-81.
44. Gao N, Kramer L, Rahmani M, Dent P, Grant S. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol- 4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol 2006;70:645-655
45. Zindy F, Quelle DE, Roussel MF, Sherr CJ. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997;15:203-211 (Pubitemid 27344559)
46. Huot TJ, Rowe J, Harland M, et al. Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol 2002;22:8135-8143 (Pubitemid 35304047)
47. Brookes S, Rowe J, Ruas M, et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 2002;21:2936-2945 (Pubitemid 34670378)
48. Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel MF. INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 2000;20:372-378 (Pubitemid 30002578)
49. Sherr CJ. Parsing Ink4a/Arf: "pure" p16-null mice. Cell 2001;106:531-534
50. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002;297:63-64